Page 59 - 2021_10-Haematologica-web

Clinical significance of chromatin-spliceosome AML
diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011;118(17):4690-4693.
4. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute mye-loid leukemia. J Clin Oncol. 2018;36(26):2684- 2692.
5.DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
6.Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32 (12):2546-2557.
7. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recom-mendations from an international expert panel. Blood. 2017;129(4):424-447.
8.de Witte T, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European intergroup trial. Haematologica. 2010;95(10):1754-1761.
9. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-1376.
10. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodys-plastic syndromes. Leukemia. 2014;28(2):241-247.
11. Makishima H, Yoshizato T, Yoshida K, et
al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204-212.
12. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leu-kemia. 2013;27(9):1861- 1869.
13. Lasho TL, Mudireddy M, Finke CM, et al. Targeted next-generation sequencing in blast phase myelopro-liferative neoplasms. Blood Adv. 2018;2(4):370-380.
14. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
15. Metzeler KH, Herold T, Rothenberg- Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686- 698.
16. Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24(8):1528-1532.
17. Bassan R, Intermesoli T, Masciulli A, et al. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Adv. 2019;3(7):1103-1117.
18. Salmoiraghi S, Cavagna R, Zanghì P, et al. High throughput molecular characteriza- tion of normal karyo-type acute myeloid leukemia in the context of the prospective trial 02/06 of the Northern Italy Leukemia Group (NILG). Cancers. 2020;12(8):2242.
19. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol.
2003;21(24):4642-4649.
20. Levine RL, Valk PJM. Next-generation
sequencing in the diagnosis and minimal residual disease as-sessment of acute myeloid leukemia. Haematologica. 2019; 104(5):868-871.
21. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syn- dromes. Blood. 2013;122(22):3616-3627.
22. Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leu-kemia. N Engl J Med. 2013;368(22):2059-2074.
23. Gardin C, Pautas C, Fournier E, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4(9):1942-1949.
24. Brierley CK, Steensma DP. Targeting spliceosome in the treatment of myelodys- plastic syndromes and other myeloid neo- plasms. Curr Hematol Malig Rep. 2016;11 (6):408-415.
25. Steensma DP, Maris MB, Yang J, et al. H3B- 8800-G0001-101: a first in human phase I study of a spliceosome modulator in patients with advanced myeloid malignan- cies. J Clin Oncol. 2017;35(Suppl 15): TPS7075.
26. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
27. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute mye-loid leukemia. Blood. 2017;130(6):722-731.
28. Röllig C, Kramer M, Schliemann C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823-830.
haematologica | 2021; 106(10)
2587